Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

 
• By Jessica Merrill

The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.

tumor microenvironment
Gilead signed a deal with Compugen for an early novel immuno-oncology asset • Source: Shutterstock

More from Deals

More from Business